Sagent Pharmaceuticals Reports First Quarter 2012 Financial Results –

Revenue increased 26% to $38.3 million driven by products launched in the last twelve months; Gross profit increased to $5.8 million, or 15.1% of net revenue on strong margins from newly launched products; Launched Midazolam and Levofloxacin in …

Leave a Reply

Your email address will not be published.